reported that in breast cancer cell lines treated with a combination of lapatinib and the lysosomal disruptor siramesine, intracellular iron levels could be significantly increased by upregulating transferrin or downregulating the transferrin receptor (34, 35). Here, TFRC is linked to breast cancer.